BACOD regimen: Difference between revisions

	WikiDoc Resources for BACOD regimen
Articles
Most recent articles on BACOD regimen Most cited articles on BACOD regimen Review articles on BACOD regimen Articles on BACOD regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on BACOD regimen Images of BACOD regimen Photos of BACOD regimen Podcasts & MP3s on BACOD regimen Videos on BACOD regimen
Evidence Based Medicine
Cochrane Collaboration on BACOD regimen Bandolier on BACOD regimen TRIP on BACOD regimen
Clinical Trials
Ongoing Trials on BACOD regimen at Clinical Trials.gov Trial results on BACOD regimen Clinical Trials on BACOD regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on BACOD regimen NICE Guidance on BACOD regimen NHS PRODIGY Guidance FDA on BACOD regimen CDC on BACOD regimen
Books
Books on BACOD regimen
News
BACOD regimen in the news Be alerted to news on BACOD regimen News trends on BACOD regimen
Commentary
Blogs on BACOD regimen
Definitions
Definitions of BACOD regimen
Patient Resources / Community
Patient resources on BACOD regimen Discussion groups on BACOD regimen Patient Handouts on BACOD regimen Directions to Hospitals Treating BACOD regimen Risk calculators and risk factors for BACOD regimen
Healthcare Provider Resources
Symptoms of BACOD regimen Causes & Risk Factors for BACOD regimen Diagnostic studies for BACOD regimen Treatment of BACOD regimen
Continuing Medical Education (CME)
CME Programs on BACOD regimen
International
BACOD regimen en Espanol BACOD regimen en Francais
Business
BACOD regimen in the Marketplace Patents on BACOD regimen
Experimental / Informatics
List of terms related to BACOD regimen

VisualWikitext

Latest revision as of 14:14, 11 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: BACOD; BLEO/CTX/DM/DOX/VCR; Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine regimen

Overview

BACOD regimen refers to an immunochemotherapy regimen consisting of bleomycin, doxorubicin, cyclophosphamide ,vincristine ,dexamethasone used to treat relapsed and refractory diffuse large B cell lymphoma .^[1]^[2]

Regimen

BBleomycin

ADoxorubicin (Adriamycin)

CCyclophosphamide

OVincristine (Oncovin)

DDexamethasone

Indications

Relapsed and refractory Diffuse large B-cell lymphoma ^[3]

References

↑ "NCI Thesaurus".
↑ "R-CHOP - National Cancer Institute".
↑ Gong G, Du J, Dong L, Lei W, Gao X, Fang B; et al. (2014). "[Efficacy of adjusted BACOD regimen on the treatment of relapsed refractory diffuse large B cell lymphoma]". Zhonghua Xue Ye Xue Za Zhi. 35 (4): 295–9. doi:10.3760/cma.j.issn.0253-2727.2014.04.010. PMID 24759015.

[1] "NCI Thesaurus".

[2] "R-CHOP - National Cancer Institute".

[pmid24759015-3] Gong G, Du J, Dong L, Lei W, Gao X, Fang B; et al. (2014). "[Efficacy of adjusted BACOD regimen on the treatment of relapsed refractory diffuse large B cell lymphoma]". Zhonghua Xue Ye Xue Za Zhi. 35 (4): 295–9. doi:10.3760/cma.j.issn.0253-2727.2014.04.010. PMID 24759015.

[1]

[2]

[3]

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AV}}
-{{SK}} BACOD
+{{SK}} BACOD; BLEO/CTX/DM/DOX/VCR; Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine regimen
-BLEO/CTX/DM/DOX/VCR
-Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine regimen
 ==Overview==
-{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[rituximab]], [[cyclophosphamide]], [[doxorubicin |hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride)]], [[vincristine|vincristine (Oncovin)]] and [[prednisone]] used to treat both indolent and aggressive forms of [[non-Hodgkin lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
+{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[bleomycin]], [[doxorubicin]], [[cyclophosphamide]] ,[[vincristine]] ,[[dexamethasone]] used to treat relapsed and refractory [[diffuse large B cell lymphoma]] .<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate =  | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref>
 ==Regimen==
-[[Rituximab|{{button|R – Rituximab}}]]
+{{chemo|B|Bleomycin}}
-[[Cyclophosphamide|{{button|C – Cyclophosphamide}}]]
+{{chemo|A|Doxorubicin (Adriamycin)}}
-[[Doxorubicin|{{button|H – Doxorubicin (Hydroxydaunomycin)}}]]
+{{chemo|C|Cyclophosphamide}}
-[[Vincristine|{{button|O – Vincristine (Oncovin)}}]]
+{{chemo|O|Vincristine (Oncovin)}}
-[[Prednisone|{{button|P – Prednisone}}]]
+{{chemo|D|Dexamethasone}}
 ==Indications==
-* [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma, untreated]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref>
+* [[Diffuse large B-cell lymphoma|Relapsed and refractory Diffuse large B-cell lymphoma]] <ref name="pmid24759015">{{cite journal| author=Gong G, Du J, Dong L, Lei W, Gao X, Fang B et al.| title=[Efficacy of adjusted BACOD regimen on the treatment of relapsed refractory diffuse large B cell lymphoma]. | journal=Zhonghua Xue Ye Xue Za Zhi | year= 2014 | volume= 35 | issue= 4 | pages= 295-9 | pmid=24759015 | doi=10.3760/cma.j.issn.0253-2727.2014.04.010 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24759015  }} </ref>
-* [[Mantle cell lymphoma]]<ref>{{Cite journal | doi = 10.1056/NEJMoa1200920 | issn = 1533-4406 | volume = 367 | issue = 6 | pages = 520–531 | last = Kluin-Nelemans | first = H. C. | coauthors = E. Hoster, O. Hermine, J. Walewski, M. Trneny, C. H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J. K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J. M. Zijlstra, R. Bouabdallah, P. J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Procházka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. André, W. Klapper, W. Hiddemann, M. Unterhalt, M. H. Dreyling | title = Treatment of older patients with mantle-cell lymphoma | journal = The New England Journal of Medicine | date = 2012-08-09 | pmid = 22873532 }}</ref>
 ==References==